COPENHAGEN, Denmark, July 1, 2024
/PRNewswire/ -- Dawn Health, the digital health company
pioneering patient-first innovation, has announced they are working
with leading global pharmaceutical company, Merck, on a
digital solution for Growth Hormone
Disorders (GHD).
Over the next two years, they will join forces to deliver a
cutting-edge, user-centric digital platform, designed to help
improve the lives of tens of thousands of patients across more than
40 countries.
By harnessing the latest AI technologies, the collaboration will
also involve exploring the integration of features such as growth
predictions and advanced personalization into the digital product,
with excitement about AI and its potential for impact on user
experience, adoption, adherence, and treatment outcomes. The
digital solution will provide support to children and young adults
living with GHD, as well as providing tools and support to their
caregivers, both at home and in a clinical setting.
With a shared commitment to improving patient lives, the
collaboration will focus on patient-centricity to deliver an
intuitive, engaging product that supports users and caregivers
throughout their treatment journey. This means speaking with
patients to truly understand their unmet needs and how the solution
can best address these, as well as hearing from caregivers and
healthcare professionals about how to best empower and support
those living with GHD.
The collaboration is already off to a strong start, with
workshops and inspiring discussions happening between the teams at
Dawn Health and Merck, as they work together to deliver a
cutting-edge platform on a global scale to improve the lives of
people living with Growth Hormone Disorders.
About Merck
Merck, a leading science and technology company, operates across
life science, healthcare and electronics. Around 63,000 employees
work to make a positive difference to millions of people's lives
every day by creating more joyful and sustainable ways to live.
From providing products and services that accelerate drug
development and manufacturing as well as discovering unique ways to
treat the most challenging diseases to enabling the intelligence of
devices – the company is everywhere. In 2023, Merck generated sales
of € 21 billion in 65 countries. Scientific exploration and
responsible entrepreneurship have been key to Merck's technological
and scientific advances. This is how Merck has thrived since its
founding in 1668. The founding family remains the majority owner of
the publicly listed company. Merck holds the global rights to the
Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck
operate as MilliporeSigma in life science, EMD Serono in
healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same
time they become available on the Merck website. Please go to
www.merckgroup.com/subscribe to register online, change your
selection or discontinue this service.
About Dawn Health
Dawn Health is a global leader in digital health, specializing
in the development of software as a medical device (SaMD) and
digital therapeutics (DTx). Partnering with pharmaceutical
companies, Dawn Health accelerates the launch of digital solutions
to change the lives of people with chronic conditions.
Media Contacts
For questions about Merck
constance.de-quinsonas@merckgroup.com
For questions about Dawn Health
Christopher Kold, +4541586088
cko@dawnhealth.com
View original
content:https://www.prnewswire.com/news-releases/dawn-health-and-merck-are-collaborating-to-support-growth-disorders-care-302184352.html
SOURCE Dawn Health A/S